By Fineline Cube 
UK-based ADVANZ PHARMA announced the acquisition of commercial rights to testoviron from German giant Bayer (ETR: BAYN) for Europe, Latin America, the Middle East, Africa, and select Asia-Pacific markets.
Agreement Details
The agreement expands ADVANZ’s andrology-focused product portfolio and is expected to enhance the company’s presence in these regions. No financial terms of the deal were disclosed.
Strategic Significance
The acquisition builds on the existing partnership between ADVANZ and Bayer. It strengthens ADVANZ’s position in the andrology market and provides access to a broader patient population.
Market Opportunity
Testoviron is a long-acting injectable testosterone formulation primarily indicated for male hypogonadism. The specific indications may vary by market and dosage form. This acquisition provides ADVANZ with new opportunities for growth and market penetration.-Fineline Info & Tech